An Open Label, Single arm, Clinical trial to assess the usefulness of CV-HFU01 tablets in management of recurrent UTI.

Climic Health Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or female patients of age 18 to 60 (both inclusive)
•2.Patients with subclinical (asymptomatic bacteriuria) and or recurrent UTI (2-3 episodes of UTI in the last 12 months)
•3.Patients with or without UTI not responding to antimicrobial therapy due to any cause including multidrug resistance.
•4.Patients prone to recurrent UTIs [like geriatric women, geriatric men with symptomatic BPH, patients on clean intermittent catheterization (CIC), chronically catheterized patients (indwelling catheter, supra pubic catheter) patients with spinal cord injury/ stroke/ paraplegia/ abnormalities of urinary tract].
•5.Patients with subclinical (asymptomatic)/recurrent UTI who are off any antibiotics for the past two weeks.
•The working definition of recurrent UTI used by us for this study: Patients with recurrent UTI ( > 2 or equal to episodes) who had culture positive/sensitive UTI and had taken multiple courses of antimicrobials in the past one year or so and desiring alternative therapy were given the option of entering in to this study

•1. Patients with the first episode of symptomatic active UTI
•2. Pregnant and or lactating patients.
•3. Patients in the pediatric age group.
•4. Patients with known history of hyperoxaluria/known renal oxalatestone formers.
•6. Patients not consenting for the study

发起方

Climic Health Pvt Ltd